About Compounded Semaglutide
How does it work?
Semaglutide copies a hormone called GLP-1 that your body releases after meals. It slows how fast your stomach empties, so you feel full longer. It signals the satiety center in your brain to cut appetite. And it improves how your body handles blood sugar after eating. The Mayo Clinic’s description of subcutaneous semaglutide outlines these mechanisms in patient-facing terms.
In the STEP-1 trial, people taking the FDA-approved branded version of semaglutide at 2.4 mg lost an average of approximately 14.9% of their body weight at 68 weeks, in a population without diabetes, according to Wilding et al. in the New England Journal of Medicine (2021). Slower digestion, reduced hunger, and better blood sugar control all work together to drive those results.
The injectable form has the strongest research behind it. Oral and sublingual compounded preparations have less trial data.
Available forms
Most often it’s a subcutaneous injection given once a week. Some pharmacies also prepare oral or sublingual versions, but these haven’t been tested in clinical trials for safety or effectiveness. The FDA-approved oral semaglutide (Rybelsus) relies on a special absorption enhancer to get the drug through the stomach lining; compounded oral and sublingual versions don’t have that technology, so how much actually gets absorbed is unknown. Dose, strength, and formulation are set by the prescriber and pharmacy together.
Your Testing-to-Treatment Journey
Step 1: Lab tests to consider first
Baseline labs give your prescriber a clear picture of where you’re starting. They help show whether semaglutide is a strong fit and set a benchmark to measure progress against.
| Test | Why it’s reviewed | What different results suggest |
| Hemoglobin A1c | Measures average blood sugar over two to three months | An A1c of 5.7–6.4% may indicate prediabetes; 6.5% or higher may indicate diabetes. Either range makes semaglutide a stronger fit because it works on blood sugar and weight together |
| Fasting insulin + glucose (HOMA-IR) | Catches insulin resistance that A1c can miss | High fasting insulin alongside normal A1c points toward early insulin resistance. A prescriber may calculate a HOMA-IR (homeostatic model assessment of insulin resistance) score to weigh GLP-1 therapy |
| Lipid panel | Cardiovascular risk context | High triglycerides and low HDL (high-density lipoprotein) fit the pattern semaglutide works on. The STEP-1 trial showed cholesterol improvements alongside weight loss |
Results are typically delivered one to two business days after the lab receives the sample.
Metabolic syndrome and GLP-1 candidacy
Many people who consider GLP-1 therapy meet the criteria for metabolic syndrome. The NHLBI defines metabolic syndrome as having three or more of the following:
- Waist over 40 inches (men) or over 35 inches (women)
- Blood pressure at or above 130/85 mmHg
- Fasting glucose at or above 100 mg/dL
- Triglycerides at or above 150 mg/dL
- HDL below 40 mg/dL (men) or below 50 mg/dL (women)
Knowing where you stand on these markers helps a prescriber prioritize. If your labs show several of these patterns together, semaglutide may address more than one risk factor at once.
Talk with a licensed provider about what your results mean.
Step 2: What happens during a prescriber consult
Your prescriber reviews your medical history, current medications, baseline labs, and weight-related goals. They screen for contraindications including medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), pancreatitis history, type 1 diabetes, and pregnancy. Candidacy generally follows the FDA-approved branded version’s labeling: a BMI of 30 or higher, or 27 or higher with a weight-related condition. The NIDDK’s overview of prescription weight-management medications describes how these candidacy thresholds are applied in clinical practice.
Both telehealth and in-person clinics offer evaluations.
Step 3: Starting therapy
You’ll start at a low weekly dose, often 0.25 mg. The dose goes up over about 16 weeks to a maintenance level based on your tolerance and response. Slow titration is designed to minimize GI side effects. Your pharmacy fills the prescription according to the prescriber’s compounded protocol, not a fixed off-the-shelf product.
Step 4: Labs to recheck on therapy
Monitoring labs tell you and your prescriber whether the medication is working and whether your body is tolerating it well.
| Recheck | Frequency | What it shows |
| Hemoglobin A1c | Every three months | Glycemic response to treatment |
| Comprehensive metabolic panel (CMP) | Every three to six months | Kidney function and electrolytes |
| Lipid panel | Every six months | Cardiovascular response |
| Weight | Weekly to monthly | Trajectory toward your goal |
From the Testing.com Medical Review Board
“The first six weeks on semaglutide tell you a lot. If you’re seeing even modest weight movement and tolerating the dose without significant nausea, that’s a good signal the titration is on track. When GI symptoms are severe or weight isn’t moving after eight to 12 weeks at a stable dose, that’s the conversation to have with your prescriber, not a reason to stop, but a reason to reassess the protocol.”
Testing.com Editorial Review Board
Safety and Side Effects
Common side effects
The most commonly reported side effects in clinical trials of the FDA-approved branded version are nausea, vomiting, diarrhea, constipation, and reduced appetite. Most peak during dose escalation in the first several weeks and ease as your body adjusts.
How to manage them
Prescribers often hold the dose at its current level longer if nausea is severe during escalation weeks. Smaller, more frequent meals help. Avoid high-fat foods around your injection day. Stay well hydrated to help with constipation. Your prescriber can suggest specific adjustments.
Some of the weight lost on semaglutide is muscle, not just fat. That matters most for older adults, where losing muscle adds to frailty risk, so resistance training and enough protein are worth discussing with your prescriber.
Serious risks and contraindications
Semaglutide carries a boxed warning for thyroid C-cell tumors, based on rodent studies whose relevance to humans isn’t established. It’s contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, a history of pancreatitis, or if you’re pregnant. It also isn’t a treatment for type 1 diabetes; using it in place of insulin there can lead to diabetic ketoacidosis. The Mayo Clinic’s semaglutide precautions page details these contraindications.
On pregnancy and fertility: animal studies showed harm to the fetus, so plan to stop semaglutide before trying to conceive unless your prescriber decides the benefits clearly outweigh the risks. By improving metabolic health it may also restore ovulation in conditions like PCOS, which can make pregnancy more likely than expected. Discuss contraception and conception timing with your prescriber.
Semaglutide and other GLP-1 drugs can raise the risk of gallbladder problems, including gallstones and inflammation. The risk rises with rapid weight loss, so tell your prescriber about sudden or severe abdominal pain.
If you have diabetes with existing diabetic retinopathy, tell your prescriber. Rapid drops in blood sugar can temporarily worsen retinopathy, so an eye exam before or soon after starting is reasonable.
Severe, lasting GI symptoms are uncommon but can signal something serious. The FDA has warned that GLP-1 drugs may cause gastroparesis (stomach paralysis), ileus, or bowel obstruction, so contact your prescriber for severe or persistent abdominal pain, vomiting, or constipation. Because semaglutide slows stomach emptying, also tell any surgeon or anesthesiologist that you take it before surgery or an endoscopy, since it can raise aspiration risk and may need to be paused.
Some people have reported mood changes or thoughts of self-harm on GLP-1 drugs. Regulators have reviewed these reports and haven’t established that the drugs cause them, but tell your prescriber right away about new or worsening depression or any thoughts of self-harm.
Go over your full medical history with your prescriber before starting.
Drug and supplement interactions
Slowed gastric emptying affects how your body absorbs oral medications, so timing matters. Don’t combine semaglutide with other GLP-1 agonists. Pairing it with insulin or sulfonylureas raises the risk of low blood sugar (hypoglycemia), and the ADA suggests lowering those doses when starting semaglutide.
Share a full medication and supplement list with your prescriber so timing can be adjusted.
Stopping the medication
In the STEP 1 trial extension, participants who stopped the FDA-approved branded version of semaglutide after 68 weeks regained approximately two-thirds of the weight they had lost over the following year, as reported by Wilding et al. in Diabetes Obes Metab (2022). Blood sugar, blood pressure, and other cardiometabolic gains tend to reverse as the weight returns.
Some prescribers taper the dose before stopping; others stop directly. Lifestyle changes and follow-up monitoring affect how much weight stays off. A stopping plan is worth discussing before you start.
Cost and Access
Cost ranges as of May 2026. Pricing varies by pharmacy and shortage status; confirm with the dispensing pharmacy before committing to a multi-month plan.
Compounded semaglutide typically costs $200–$500 per month out of pocket. Insurance rarely covers compounded medications, so most people pay cash. HSA (health savings account) and FSA (flexible spending account) eligibility depends on your prescriber’s documentation and your plan administrator.
Cost breakdown by pharmacy tier
Costs vary depending on the type of pharmacy that fills your prescription.
| Tier | Typical monthly cost | Notes |
| 503A compounded (single-patient pharmacy) | $200–$500 | Prescription-specific; insurance rarely covers |
| 503B compounded (outsourcing facility) | $250–$600 | Available through clinics; FDA-registered oversight |
| FDA-approved branded version of semaglutide | $900–$1,350 | Insurance coverage varies by indication |
Price variation reflects shortage status, multi-month supply plans, and the specific pharmacy’s pricing. Check current availability with a licensed prescriber.
What makes compounded semaglutide different
Compounded semaglutide is not an FDA-approved finished drug product. It’s prepared by a licensed compounding pharmacy under a valid prescription. The FDA’s compounding overview explains the difference between 503A pharmacies, which compound for individual patients, and 503B outsourcing facilities, which produce larger batches under FDA-registered oversight. Both require a prescription. The FDA-approved branded version goes through a different regulatory pathway and is approved as a finished product.
Compounded vs branded pricing
Compounded preparations cost less than the FDA-approved branded version. Insurance coverage patterns favor branded products when prescribed for labeled indications. Shortage status and pharmacy type drive most of the price variation you’ll see.
How to get it
You’ll need a prescription from a licensed provider. Telehealth platforms that route prescriptions to compounding pharmacies are a common access route, as are in-person weight management clinics. HSA and FSA eligibility depends on the prescriber’s documentation and your plan administrator. Compounding availability has been affected by FDA shortage-list changes; the FDA’s semaglutide safety communications page tracks current regulatory status. Check current access with a licensed prescriber before you start.
Frequently Asked Questions
Sources
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002.
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP-4). JAMA. 2021;325(14):1414-1425.
American Diabetes Association. Standards of Medical Care in Diabetes: Glycemic Targets. 2025.
National Heart, Lung, and Blood Institute. Metabolic Syndrome. NIH.
U. S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
Mayo Clinic. Semaglutide (Subcutaneous Route): Description.
Mayo Clinic. Semaglutide (Subcutaneous Route): Precautions.
Cleveland Clinic. GLP-1 Agonists.
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP-1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564.